SCHEMBL204390

SCHEMBL204390

Nc1nc2cccnc2c2c1nc1cccnn12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.42
HRH4 Q9H3N8 1/20 0.35
DHFR P00374 1/20 0.33
TLR7 Q9NYK1 4/20 0.33
PDE4D Q08499 3/20 0.33
PDE4B Q07343 2/20 0.33
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
MKNK1 Q9BUB5 2/20 0.33
CDK1 P06493 1/20 0.33
CDK2 P24941 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
KDM4E B2RXH2 3/20 0.32
MAPT P10636 2/20 0.32
ALDH1A1 P00352 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TLR8 Q9NR97 1/20 0.32
TOP1 P11387 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203984 0.82 TLR7 (0.46) TLR7PDE4DTLR8LMNAPOLB
SCHEMBL205143 0.76 KDM4E (0.40) PRMT5PDE4DPDE4BPDE4APDE4C
SCHEMBL10123111 0.72 PRMT5 (0.50) PRMT5HRH4DHFRTLR7PDE4D
SCHEMBL13588390 0.71 PRMT5 (0.47) PRMT5HRH4TLR7TLR8LMNA
SCHEMBL4299811 0.71 TLR7 (0.42) PRMT5HRH4DHFRTLR7PDE4D
SCHEMBL203433 0.69 PRMT5 (0.40) PRMT5HRH4DHFRTLR7MKNK1
SCHEMBL5809073 0.69 PRMT5 (0.43) PRMT5HRH4TLR7PDE4DTLR8
SCHEMBL202005 0.68 KDM4E (0.42) PRMT5HRH4DHFRTLR7MKNK1
SCHEMBL12888373 0.68 TLR7 (0.53) PRMT5TLR7TLR8
SCHEMBL4383648 0.67 PRMT5 (0.38) PRMT5HRH4TLR7TLR8HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088788-B2 Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-01-03 US disclosed
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS PFIZER INC. 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221551-A1 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS IL2, IFNG, IL4 PRMT5 959/4885HRH4 94/4885DHFR 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.